SCHEMBL26955849

SCHEMBL26955849

Cc1cnc(Nc2ccc(Cl)nc2)c2[nH]ccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 1/20 0.45
▸ AXL P30530 1/20 0.43
▸ PRKCI P41743 1/20 0.43
▸ GRM4 Q14833 1/20 0.40
▸ KCNQ3 O43525 3/20 0.39
▸ KCNQ2 O43526 3/20 0.39
▸ KCNQ1 P51787 2/20 0.39
▸ TRPA1 O75762 1/20 0.39
▸ SCN5A Q14524 1/20 0.39
▸ TTBK1 Q5TCY1 4/20 0.39
▸ TTBK2 Q6IQ55 4/20 0.39
▸ PIK3CA P42336 2/20 0.38
▸ CCNT1 O60563 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CDK4 P11802 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCND1 P24385 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ CDK7 P50613 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30824397 1.00 TNF (0.45) TNFAXLPRKCIGRM4KCNQ3
SCHEMBL26957527 0.83 TTBK1 (0.41) TNFGRM4KCNQ3KCNQ2KCNQ1
Formic Acid SCHEMBL26928975 0.78 KCNQ3 (0.38) TNFGRM4KCNQ3KCNQ2KCNQ1
Formic Acid SCHEMBL30738049 0.78 KCNQ3 (0.38) TNFGRM4KCNQ3KCNQ2KCNQ1
SCHEMBL30738486 0.76 KCNQ3 (0.43) TNFGRM4KCNQ3KCNQ2KCNQ1
SCHEMBL26957346 0.76 KCNQ3 (0.43) TNFGRM4KCNQ3KCNQ2KCNQ1
SCHEMBL26957347 0.75 L3MBTL1 (0.43) GRM4KCNQ3KCNQ2KCNQ1TRPA1
SCHEMBL30824351 0.75 GRM4 (0.45) TNFGRM4KCNQ3KCNQ2KCNQ1
SCHEMBL26957515 0.75 GRM4 (0.45) TNFGRM4KCNQ3KCNQ2KCNQ1
SCHEMBL2628869 0.71 AXL (0.53) AXLPRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 — — US claimed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 — — US disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 TNF 4805/4885AXL 2891/4885PRKCI 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback